natgillin/translations-raw huggingface dataset:
Blandt 1.166 patienter i behandling med lenvatinib blev blødning af grad 3 eller højere rapporteret hos 2 % af patienterne, 3 patienter (0,3 %) havde en grad 4 blødning, og 5 patienter (0,4 %) havde en grad 5 reaktion, herunder arteriel blødning, hjerneblødning, intrakranial tumorblødning, hæmoptyse og tumorblødning. 
Amongst 1,166 patients treated with lenvatinib, Grade 3 or greater haemorrhage was reported in 2% of patients, 3 patients (0.3%) had a Grade 4 haemorrhage and 5 patients (0.4%) had a Grade 5 reaction including arterial haemorrhage, haemorrhagic stroke, intracranial tumour haemorrhage, haemoptysis and tumour haemorrhage.
Gastrointestinal perforation og fisteldannelse 
Gastrointestinal perforation and fistula formation
Blandt 1.166 patienter behandlet med lenvatinib var der 5 tilfælde (0,4 %) af arteriel tromboemboli (3 tilfælde af myokardieinfarkt og 2 cerebrovaskulære tilfælde) med dødelig udgang. 
Amongst 1,166 patients treated with lenvatinib, there were 5 cases (0.4%) of arterial thromboembolisms (3 cases of myocardial infarction and 2 cases of cerebrovascular accident) with a fatal outcome.
Forekomsten af QTc-interval på over 500 ms var 6 % i lenvatinib plus everolimus-gruppen. 
The incidence of QTc interval greater than 500 ms was 6% in the lenvatinib plus everolimus-treated group.
Den anbefalede daglige dosis af lenvatinib er 18 mg (én 10 mg kapsel og to 4 mg kapsler) én gang dagligt i kombination med 5 mg everolimus én gang dagligt. 
The recommended daily dose of lenvatinib is 18 mg (one 10 mg capsule and two 4 mg capsules) once daily in combination with 5 mg of everolimus once daily.
Der var ingen rapporter i grupperne med lenvatinib plus everolimus eller everolimus-monoterapi. 
There were no reports in the lenvatinib plus everolimus or everolimus monotherapy groups.
Prævention, graviditet og amning 
Contraception, pregnancy and breast-feeding
Kisplyx kan startes igen, når det vurderes, 
Kisplyx may be restarted once adequate wound healing is established.
Hvis du har taget for meget Kisplyx 
If you take more Kisplyx than you should
Reaktioner, der opstod med en forekomst på ≥ 2,0 %, var: epistaxis (22,6 %), hæmaturi (4,8 %), hæmatom (3,2 %) og gastrisk blødning (3,2 %). 
Reactions that occurred at an incidence of ≥2.0% were: epistaxis (22.6%), haematuria (4.8%), haematoma (3.2%), and gastric haemorrhage (3.2%).
Grad 3 reaktioner forekom hos 10,7 % af patienterne i lenvatinib-gruppen og hos ingen i placebogruppen. 
Grade 3 reactions occurred in 10.7% of lenvatinib-treated patients and none in placebo-treated patients.
Patienter med DTC og lav legemsvægt (< 60 kg) havde imidlertid en højere forekomst af PPE, proteinuri, grad 3 eller 4 hypokalcæmi og hyponatriæmi og en tendens til højere forekomst af grad 3 eller 4 appetitløshed. 
However in DTC patients with low body weight (<60 kg) had a higher incidence of PPE, proteinuria, of Grade 3 or 4 hypocalcaemia and hyponatraemia, and a trend towards a higher incidence of Grade 3 or 4 decreased appetite.
Hvis du har taget for meget Kisplyx, skal du straks kontakte lægen eller apotekspersonalet. 
If you take more Kisplyx than you should, talk to a doctor or pharmacist straight away.
Lenvatinibs farmakokinetik efter en enkelt dosis på 10 mg blev evalueret hos 6 personer med let og 6 personer med moderat nedsat leverfunktion (Child-Pugh A hhv. Child-Pugh B). 
The pharmacokinetics of lenvatinib following a single 10-mg dose were evaluated in 6 subjects each with mild and moderate hepatic impairment (Child-Pugh A and Child-Pugh B, respectively).
Patienter ≥ 75 år med DTC havde imidlertid en større tendens til grad 3 eller 4 hypertension, proteinuri, nedsat appetit og dehydrering. 
However, in DTC, patients of age ≥75 years were more likely to experience Grade 3 or 4 hypertension, proteinuria, decreased appetite, and dehydration.
Alvorlige tumorrelaterede blødninger, herunder blødning med dødelig udgang, er forekommet i kliniske studier og er blevet rapporteret efter markedsføring (se pkt. 
Serious tumour related bleeds, including fatal haemorrhagic events have occurred in clinical trials and have been reported in post-marketing experience (see section 4.8, Description of selected adverse reactions).
I everolimus-gruppen blev der rapporteret arteriel tromboemboli hos 6,0 % af patienterne (4,0 % var grad ≥ 3). 
In the everolimus group, 6.0% of patients reported an arterial thromboembolism (4.0% were Grade ≥ 3).
Blandt 1.166 patienter behandlet med lenvatinib var der 4 tilfælde (0,3 %) af PRES (alle var grad 3 eller 4), som alle fortog sig efter behandling og/eller doseringsafbrydelse eller permanent seponering. 
Amongst 1,166 patients treated with lenvatinib, there were 4 cases (0.3%) of PRES (0.3% were Grade 3 or 4), all of which resolved after treatment and/or dose interruption, or permanent discontinuation.
• Den anbefalede daglige dosis af Kisplyx er 18 mg én gang dagligt (en 10 mg kapsel og to 4 mg kapsler) sammen med en 5 mg tablet everolimus én gang dagligt. 
• The recommended daily dose of Kisplyx is 18 mg once a day (one 10 mg capsule and two 4 mg capsules) in combination with one 5 mg tablet of everolimus once a day.
De fleste tilfælde blev bedre eller fortog sig efter doseringsafbrydelse eller dosisreduktion, hos hhv. 13,0 % og 13,4 % af patienterne. 
The majority of cases recovered or resolved following dose interruption or reduction, which occurred in 13.0% and 13.4% of patients, respectively.
Rygsmerter Artralgi Myalgi Ekstremitetssmerter Muskuloskeletale smerter 
Back pain Arthralgia Myalgia Pain in extremity Musculoskeletal pain
Hos patienter med en normal TSH ved baseline blev der observeret forhøjet TSH efter baseline hos 60,5 % af patienterne i lenvatinib plus everolimus-gruppen sammenlignet med ingen i everolimus-gruppen. 
In patients with a normal TSH at baseline, an elevation of TSH level was observed post baseline in 60.5% of lenvatinib plus everolimus-treated patients as compared with none in patients receiving everolimus alone.
Reaktioner af grad 3 eller derover (herunder 1 grad 4 reaktion) forekom hos 44,4 % af patienterne i lenvatinib-gruppen sammenlignet med 3,8 % i placebogruppen. 
Reactions of Grade 3 or higher (including 1 reaction of Grade 4) occurred in 44.4% of lenvatinib-treated patients compared with 3.8% of placebo-treated patients.
Resultater for ORR var i overensstemmelse med investigatorernes bedømmelser, 35,3 % i lenvatinib plus everolimus-armen med et fuldstændigt respons og 17 med delvist respons. 
Results for ORR were consistent with that of the investigators' assessments, 35.3% in the lenvatinib plus everolimus arm, with one complete response and 17 partial responses; no subject had an objective response in the everolimus arm (P < 0.0001) in favour of the lenvatinib plus everolimus arm.
For toksiciteter, der menes at være forbundet med lenvatinib (se tabel 1), kan behandlingen genoptages med en reduceret dosis lenvatinib, som foreslået i tabel 2, når bivirkningen har fortaget sig eller er bedret til grad 0-1 eller baseline-niveau. 
For toxicities thought to be related to lenvatinib (see Table 1), upon resolution/improvement of an adverse reaction to Grade 0-1 or baseline, treatment should be resumed at a reduced dose of lenvatinib as suggested in Table 2.
Reaktioner, der opstod med en forekomst på ≥ 0,75 % over placebo, var: epistaxis (11,9 %), hæmaturi (6,5 %), kontusion (4,6 %), gingivalblødning (2,3 %), hæmatokeksi (2,3 %), rektalblødning (1,5 %), hæmatom (1,1 %), blødende hæmorroider (1,1 %), laryngeal blødning (1,1 %), petekkier (1,1 %) og intrakranial tumorblødning (0,8 %). 
Reactions that occurred at an incidence of ≥0.75% above placebo were: epistaxis (11.9%), haematuria (6.5%), contusion (4.6%), gingival bleeding (2.3%), haematochezia (2.3%), rectal haemorrhage (1.5%), haematoma (1.1%), haemorrhoidal haemorrhage (1.1%), laryngeal haemorrhage (1.1%), petechiae (1.1%), and intracranial tumour haemorrhage (0.8%).
Der er begrænsede data for patienter med legemsvægt under 60 kg med RCC (se også pkt. 
Limited data are available on patients with a body weight below 60 kg with RCC (see also section 4.8, Other special populations).
De observerede bivirkninger i kliniske studier med RCC og DTC var sammenlignelige. 
Tabulated list of adverse reactions for RCC and DTC studies Similar adverse reactions were observed in clinical trials in RCC and DTC.
PRES (også kaldet RPLS) er blevet rapporteret hos patienter i behandling med lenvatinib (< 1 %, se pkt. 
PRES, also known as RPLS, has been reported in patients treated with lenvatinib (<1%; see section 4.8, Description of selected adverse reactions).
Lenvatinib hæmmede ikke aldehydoxidase-aktiviteten i human lever-cytosol. 
In human liver cytosol, lenvatinib did not inhibit aldehyde oxidase activity.
Seponer lenvatinib og påbegynd passende behandling. 
Discontinue lenvatinib and institute appropriate medical management.
Patienter med RCC og nedsat nyrefunktion ved baseline havde en højere forekomst af grad 3 træthed. 
In RCC, patients with baseline renal impairment had a higher incidence of Grade 3 fatigue.
Hos patienter med DTC havde kvinder en højere forekomst af hypertension (herunder grad 3 eller 4 hypertension), proteinuri og palmoplantar erytrodysæstesisyndrom (PPE), og mænd havde en højere forekomst af nedsat uddrivningsfraktion samt gastrointestinal perforation og fisteldannelse. 
In patients with DTC, females had a higher incidence of hypertension (including Grade 3 or 4 hypertension), proteinuria, and PPE, while males had a higher incidence of decreased ejection fraction and gastrointestinal perforation and fistula formation.
Fistel uden for mave-tarm-kanalen omfatter tilfælde af fistler uden for mave og tarme, såsom trakeal, trakeoøsofageal, øsofageal fistel samt fistel i de kvindelige kønsorganer og kutan fistel. 
Non-gastrointestinal fistula includes cases of fistula occurring outside of the stomach and intestines such as tracheal, tracheo-oesophageal, oesophageal, female genital tract fistula, and cutaneous fistula.
Gastrointestinal perforation og fisteldannelse (se pkt. 
Gastrointestinal perforation and fistula formation (see section 4.4)
I DTC-studiet (se produktresuméet for Lenvima) havde 88 % af alle patienter et baseline-niveau af TSH ≤ 0,5 mE/l. 
In the DTC study (see Lenvima SmPC), 88% of all patients had a baseline TSH level less than or equal to 0.5 mU/L.
I DTC-studiet blev hændelser med gastrointestinal perforation eller fisteldannelse rapporteret hos 1,9 % af patienterne i lenvatinib-gruppen og hos 0,8 % i placebogruppen. 
In the DTC study, events of gastrointestinal perforation or fistula were reported in 1.9% of lenvatinib-treated patients and 0.8% of patients in the placebo group.
Hver karton indeholder 30, 60 eller 90 hårde kapsler. 
Each carton contains 30, 60, or 90hard capsules.Not all pack sizes may be marketed.
Det endokrine system Hypotyroidisme** Forhøjet niveau af thyreoideastimulere nde hormon i blodet‡** 
Hypothyroidism** Blood thyroid stimulating hormone increased‡**
I DTC-studiet (se produktresuméet for Lenvima) var de hyppigst rapporterede leverrelaterede bivirkninger hypoalbuminæmi (9,6 % lenvatinib versus 1,5 % placebo) og forhøjede leverenzymer, herunder forhøjet alanin-aminotransferase (7,7 % lenvatinib versus 0 placebo), aspartataminotransferase (6,9 % lenvatinib versus 1,5 % placebo) og blod-bilirubin (1,9 % lenvatinib versus 0 placebo). 
In the DTC study (see Lenvima SmPC), the most commonly reported liver-related adverse reactions were hypoalbuminaemia (9.6% lenvatinib vs. 1.5% placebo) and elevations of liver enzyme levels, including increases in alanine aminotransferase (7.7% lenvatinib vs. 0 placebo), aspartate aminotransferase (6.9% lenvatinib vs. 1.5% placebo), and blood bilirubin (1.9% lenvatinib vs. 0 placebo).
Bivirkningerne opstillet i dette afsnit er baseret på de kombinerede sikkerhedsdata fra 62 RCCpatienter (se pkt. 
The adverse reactions presented in this section are based on the combined safety data of 62 RCC patients (see section 5.1) and 458 DTC patients (see Lenvima SmPC).
Hovedparten af tilfælden blev bedre eller fortog sig efter doseringsafbrydelse eller dosisreduktion, hos hhv. 16,9 % og 10,7 % af patienterne. 
The majority of cases had an outcome of recovered or resolved following dose interruption or reduction, which occurred in 16.9% and 10.7% of patients, respectively.
Lenvatinib kan som andre stoffer i den samme klasse have negativ indvirkning på sårhelingsprocessen. 
Lenvatinib may adversely affect the wound healing process as do other agents of the same class.
Efter du har drukket den, hælder du samme mængde vand eller æblejuice i glasset, hvirvler væsken rundt og drikker den. 
After drinking, add the same amount of water or apple juice, swirl and swallow.
Hos patienter med svært nedsat nyrefunktion er den anbefalede startdosis 10 mg lenvatinib med 5 mg everolimus én gang dagligt. 
In patients with severe renal impairment, the recommended starting dose is 10 mg of lenvatinib with 5 mg of everolimus taken once daily.
Der skal udvises forsigtighed hos patienter, der får lægemidler med virkning på renin-angiotension-aldosteron systemet, da der er en potentielt højere risiko for akut nyresvigt med denne kombinationsbehandling.Doseringsafbrydelse, dosisjustering eller seponering kan være nødvendig (se pkt. 
Caution should be taken in patients receiving agents acting on the renin-angiotensin aldosterone system given a potentially higher risk for acute renal failure with the combination treatment.
Hos patienter lå medianen for det tilsyneladende fordelingsvolumen (Vz/F) for den første dosis i intervallet fra 50,5 l til 92 l, og det var generelt konsistent i dosisgrupper fra 3,2 mg til 32 mg. Analogt hermed var det mediane tilsyneladende fordelingsvolumen ved steady state (Vz/Fss) også generelt konsistent og i intervallet fra 43,2 l til 121 l. 
In patients, the median apparent volume of distribution (Vz/F) of the first dose ranged from 50.5 L to 92 L and was generally consistent across the dose groups from 3.2 mg to 32 mg.
Tabel 2 Dosisjustering i forhold til den anbefalede daglige dosis lenvatiniba Dosisniveau 
Table 2 Dose modifications from recommended lenvatinib daily dose a
Patienter med DTC og hypertension ved baseline havde en højere forekomst af grad 3 eller 4 hypertension, proteinuri, diarré og dehydrering og oplevede mere alvorlige tilfælde af dehydrering, hypotension, lungeemboli, malign pleuraeffusion, atrieflimmer og gastrointestinale symptomer (abdominalsmerter, diarré, opkastning). 
In DTC, patients with baseline hypertension had a higher incidence of Grade 3 or 4 hypertension, proteinuria, diarrhoea, and dehydration, and experienced more serious cases of dehydration, hypotension, pulmonary embolism, malignant pleural effusion, atrial fibrillation, and GI symptoms (abdominal pain, diarrhoea, vomiting).
For at undgå gentagen eksponering for indholdet må omsorgspersoner ikke åbne kapslerne. 
Caregivers should not open the capsule, in order to avoid repeated exposure to the contents of the capsule.
Leverrelaterede reaktioner af grad 3 eller derover (herunder 1 grad 5 tilfælde af leversvigt) forekom hos 5,4 % af patienterne i lenvatinib-gruppen sammenlignet med 0,8 % i placebogruppen. 
Liver-related reactions of Grade 3 or higher (including 1 Grade 5 case of hepatic failure) occurred in 5.4% of lenvatinib-treated patients compared with 0.8% in placebo-treated patients.
Hos patienter med svært (Child-Pugh C) nedsat leverfunktion er den anbefalede startdosis 10 mg lenvatinib én gang dagligt med den dosis af everolimus, der anbefales til patienter med svært nedsat leverfunktion i produktresuméet for everolimus. 
In patients with severe (Child-Pugh C) hepatic impairment, the recommended starting dose of lenvatinib is 10 mg taken once daily in combination with the dose of everolimus recommended for patients with severe hepatic impairment in the everolimus SmPC.
De vigtigste alvorlige bivirkninger var nyresvigt og nedsat nyrefunktion (11,3 %), arteriel tromboemboli (3,9 %)*, hjertesvigt (1,6 %), cerebral blødning (1,6 %), intrakranial tumorblødning (0,7 %)*, PRES/RPLS (0,2 %)* og leversvigt (0,2 %)*. 
The most important serious adverse reactions were renal failure and impairment (11.3%), arterial thromboembolisms (3.9%)*, cardiac failure (1.6%), cerebral haemorrhage (1.6%), intracranial tumour haemorrhage (0.7%)*, PRES / RPLS (0.2%)*, and hepatic failure (0.2%)* (the asterisked frequencies are from the DTC patient population).
Mediantiden til første forekomst hos patienter i lenvatinib-gruppen var 10,1 uger. 
The median time to first onset in lenvatinib-treated patients was 10.1 weeks.
Mediantiden til start af leverrelaterede reaktioner i lenvatinib-gruppen var 12,1 uger. 
The median time to onset of liver reactions in lenvatinib-treated patients was 12.1 weeks.
Patienter med DTC og nedsat leverfunktion ved baseline havde imidlertid en højere forekomst af hypertension og PPE og højere forekomst af grad 3 eller 4 hypertension, asteni, træthed og hypokalcæmi sammenlignet med patienter med normal leverfunktion. 
However in DTC, patients with baseline hepatic impairment had a higher incidence of hypertension and PPE, and a higher incidence of Grade 3 or 4 hypertension, asthenia, fatigue, and hypocalcaemia compared with patients with normal hepatic function.
Gastrointestinal perforation eller fisteldannelse er blevet rapporteret hos patienter i behandling med lenvatinib (se pkt. 
Gastrointestinal perforation or fistulae have been reported in patients treated with lenvatinib (see section 4.8).
På samme måde postuleres det, at virkningsmekanismen i forbindelse med proteinuri medieres via nedregulering af VEGFR1 og VEGFR2 i podocytterne i glomerulus, selvom det ikke er blevet undersøgt direkte. 
Similarly, although not studied directly, the MOA for proteinuria is postulated to be mediated by downregulation of VEGFR1 and VEGFR2 in the podocytes of the glomerulus.
Forlængelse af QT/QTc-intervallet er blevet rapporteret med en højere forekomst hos patienter i behandling med lenvatinib end hos patienter i placebogruppen (se pkt. 
QT/QTc interval prolongation has been reported at a higher incidence in patients treated with lenvatinib than in patients treated with placebo (see section 4.8, Description of selected adverse reactions).
Hvis proteinuri ≥ 2+ detekteres med urinstix, kan doseringsafbrydelse, dosisjustering eller seponering være nødvendig (se pkt. 
If urine dipstick proteinuria ≥2+ is detected, dose interruptions, adjustments, or discontinuation may be necessary (see section 4.2).
Sådan virker Kisplyx 
How Kisplyx works
Patienter med DTC og nedsat nyrefunktion ved baseline havde en højere forekomst af grad 3 eller 4 hypertension, proteinuri, træthed, stomatitis, perifert ødem, trombocytopeni, dehydrering, QTforlængelse på elektrokardiogram, hypotyreoidisme, hyponatriæmi, forhøjet TSH i blodet og pneumoni sammenlignet med personer med normal nyrefunktion. 
In DTC, patients with baseline renal impairment had a higher incidence of Grade 3 or 4 hypertension, proteinuria, fatigue, stomatitis, oedema peripheral, thrombocytopenia, dehydration, prolonged electrocardiogram QT, hypothyroidism, hyponatraemia, blood thyroid stimulating hormone increased, pneumonia compared with subjects with normal renal function.
I DTC-studiet (se produktresuméet for Lenvima) blev forlængelse af QT/QTc-intervallet rapporteret hos 8,8 % af patienterne i lenvatinib-gruppen og hos 1,5 % i placebogruppen. 
In the DTC study (see Lenvima SmPC), QT/QTc interval prolongation was reported in 8.8% of lenvatinibtreated patients and 1.5% of patients in the placebo group.
I everolimus-gruppen udviklede 2,0 % af patienterne nyresvigt (2,0 % var grad 3). 
In the everolimus monotherapy group 2.0% of patients developed renal failure (2.0% were Grade 3).
Arteriel tromboemboli (apopleksi, transitorisk cerebral iskæmi og myokardieinfarkt) er blevet rapporteret hos patienter i behandling med lenvatinib (se pkt. 
Arterial thromboembolisms (cerebrovascular accident, transient ischaemic attack, and myocardial infarction) have been reported in patients treated with lenvatinib (see section 4.8, Description of selected adverse reactions).
Der er begrænsede data for asiatiske patienter med RCC. Asiatiske patienter med DTC havde imidlertid en højere forekomst end kaukasiske patienter af perifert ødem, hypertension, træthed, PPE, proteinuri, trombocytopeni og forhøjet TSH i blodet. 
However, in DTC Asian patients had a higher incidence than Caucasian patients of peripheral oedema, hypertension, fatigue, PPE, proteinuria, thrombocytopenia, and blood thyroid stimulating hormone increased.
10 mg oralt én gang dagligt 
10 mg orally once daily One 10 mg capsule
Der foreligger kun begrænsede data for doser under 8 mg. 
8 mg orally once daily Two 4 mg capsules a Limited data are available for doses below 8 mg
LÆGEMIDLETS NAVN Kisplyx 4 mg hårde kapsler Kisplyx 10 mg hårde kapsler 
NAME OF THE MEDICINAL PRODUCT Kisplyx 4 mg hard capsules Kisplyx 10 mg hard capsules
I lyset af den reducerede tolerabilitet af lenvatinib hos asiatiske og ældre patienter bør lenvatinib anvendes med forsigtighed hos sådanne patienter (se pkt. 
Lenvatinib should be used with caution in such patients, given the reduced tolerability of lenvatinib in Asian and elderly patients (see section 4.8, Other special populations).
Arteriel tromboemboli 
Arterial thromboembolisms
5.1) var de hyppigst rapporterede leverrelaterede bivirkninger i lenvatinib plus everolimus-gruppen forhøjede leverenzymer, herunder forhøjet alanin-aminotransferase (9,7 %), aspartat-aminotransferase (4,8 %), basisk fosfatase (4,8 %) og blod-bilirubin (3,2 %). 
In the RCC study (see section 5.1), the most commonly reported liver-related adverse reactions in the lenvatinib plus everolimus-treated group were elevations of liver enzyme levels, including increases in alanine aminotransferase (9.7%), aspartate aminotransferase (4.8%), alkaline phosphatase (4.8%), and blood bilirubin (3.2%).
Grad 3 leverrelaterede reaktioner forekom hos 3,2 % af patienterne i lenvatinib plus everolimus-gruppen. 
Grade 3 liver-related reactions occurred in 3.2% of lenvatinib plus everolimus-treated patients.
Progressionsfri overlevelse (PFS)a efter investigators bedømmelse Median PFS i måneder (95 % 
Progression-free survival (PFS)a by Investigator Assessment
Lenvatinib er en receptortyrosinkinase (RTK)-hæmmer, der selektivt hæmmer kinaseaktiviteten af vaskulær endotel-vækstfaktor (VEGF)-receptorerne VEGFR1 (FLT1), VEGFR2 (KDR) og VEGFR3 (FLT4) foruden andre proangiogene og onkogene reaktionsvejsrelaterede RTK'er, herunder fibroblastvækstfaktor (FGF)-receptorerne FGFR1, 2, 3 og 4, trombocytderiveret vækstfaktor (PDGF)receptor PDGFRα, KIT og RET. Kombinationen med lenvatinib og everolimus viste en øget antiangiogen og antitumor-aktivitet, vist ved reduceret human endotelcelleproliferation, rørdannelse og VEGF-signalering in vitro og et tumorvolumen hos muse-xenograftmodeller af human nyrecellecancer, der var større end for hvert af de enkelte lægemidler. 
Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that selectively inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4), in addition to other proangiogenic and oncogenic pathway-related RTKs including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4, the platelet derived growth factor (PDGF) receptor PDGFRα, KIT, and RET.
Alle patienter var tidligere blevet behandlet med 1 VEGF-hæmmer, 65 % med sunitinib, 23 % med pazopanib, 4 % med tivozanib, 3 % med bevacizumab og 2 % hver med sorafenib eller axitinib. 
The median time from diagnosis to first dose was 32 months in the lenvatinib plus everolimus-treatment arm, 33 months in the lenvatinib arm and 26 months in the everolimus arm. All patients had been treated with 1 prior VEGF-inhibitor; 65% with sunitinib, 23% with pazopanib, 4% with tivozanib, 3% with bevacizumab, and 2% each with sorafenib or axitinib.
Patienter med RCC og hypertension ved baseline havde en højere forekomst af grad 3 eller 4 dehydrering, træthed og hypertension. 
In RCC, patients with baseline hypertension had a higher incidence of Grade 3 or 4 dehydration, fatigue, and hypertension.